Can upadacitinib and betamethasone pulse therapy be used to treat vitiligo in a 48-year-old man?

Can Upadacitinib and Betamethasone Pulse Be Used for Vitiligo in a 48-Year-Old Man?

Yes, upadacitinib can be used for vitiligo in this patient and has demonstrated significant efficacy, but betamethasone pulse therapy should NOT be used due to unacceptable side effects. 1, 2

The Evidence Against Betamethasone Pulse Therapy

The British Journal of Dermatology guidelines explicitly state: "The use of oral dexamethasone to arrest progression of vitiligo cannot be recommended due to an unacceptable risk of side-effects (B/2++)" 1. This is a Grade B recommendation based on moderate-quality evidence, and applies to all systemic corticosteroids including betamethasone pulse therapy.

While older research from 1993 showed betamethasone mini-pulse (5 mg on 2 consecutive days per week) could arrest disease progression in 89% of patients 3, this approach has been superseded by guideline recommendations against systemic steroids. The side effects included weight gain, headache, weakness, and other systemic complications that make this approach unacceptable by current standards.

The Evidence FOR Upadacitinib

Upadacitinib 15 mg daily is now the evidence-based choice for vitiligo treatment, supported by the most recent and highest-quality data:

Phase 3 Trial Results (2026)

The landmark Viti-Up studies 2 demonstrated:

• T-VASI 50 (≥50% total body repigmentation) at 48 weeks: 19-21% with upadacitinib vs 6% with placebo (p<0.001)
• F-VASI 75 (≥75% facial repigmentation) at 48 weeks: 23-25% with upadacitinib vs 6-7% with placebo (p<0.001)
• Included adults and adolescents ≥12 years with non-segmental vitiligo
• No major adverse cardiovascular events, venous thromboembolism, GI perforations, tuberculosis, lymphoma, or opportunistic infections (except herpes zoster)

Phase 2 Data (2024)

Earlier dose-ranging studies 4 showed:

• Upadacitinib 11 mg and 22 mg both superior to placebo
• Continuous repigmentation through 52 weeks without plateau
• Based on these findings, 15 mg was selected as the optimal dose for phase 3 trials

Real-World Evidence

Multiple case series confirm efficacy 5, 6, 7:

• Repigmentation achieved in all treated patients
• CXCL9 levels decreased after treatment
• Well-tolerated with manageable side effects
• Combination with 308 nm excimer light may enhance results 6

Clinical Algorithm for This Patient

For a 48-year-old man with vitiligo:

1. Confirm diagnosis: Non-segmental vitiligo with F-VASI ≥0.5 and T-VASI 5-50 (typical inclusion criteria)

2. Check thyroid function: High prevalence of autoimmune thyroid disease in vitiligo patients 1

3. Initiate upadacitinib 15 mg orally once daily 8, 2

   • FDA-approved formulation (RINVOQ)
   • Can be taken with or without food
   • Steady-state achieved within 4 days

4. Monitor response:

   • Serial photographs every 2-3 months 1
   • Expect initial response within 2-4 months
   • Continue treatment through 48-52 weeks for optimal results

5. Dose adjustments (if needed):

   • Moderate hepatic impairment: No adjustment needed 8
   • Moderate renal impairment: No adjustment needed 8
   • Avoid strong CYP3A4 inhibitors or adjust dose 8

Important Safety Considerations

Common pitfalls to avoid:

• Do NOT use systemic corticosteroids (betamethasone/dexamethasone pulse) per current guidelines 1
• Monitor for herpes zoster (most common opportunistic infection with JAK inhibitors) 2
• Screen for tuberculosis before initiating therapy 9
• Avoid in patients with severe hepatic impairment (not studied) 8

Drug interactions:

• Strong CYP3A4 inhibitors (ketoconazole) increase upadacitinib exposure by 75% 8
• Strong CYP3A4 inducers (rifampin) decrease exposure by 61% 8
• Methotrexate has no clinically relevant interaction 8

Alternative Approaches (If Upadacitinib Unavailable)

If upadacitinib cannot be used, the guideline-recommended approach is 1:

1. Topical potent/very potent corticosteroids for ≤2 months (risk of skin atrophy)
2. Topical calcineurin inhibitors (pimecrolimus/tacrolimus) - better safety profile
3. NB-UVB phototherapy for widespread disease or significant QOL impact (preferred over PUVA)
4. Surgical treatments only for stable disease (no new lesions for 12 months)

The bottom line: Use upadacitinib 15 mg daily, not betamethasone pulse therapy, for this patient with vitiligo. The evidence is clear, recent, and compelling. 2